A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Scott, Aaron; H. O’Neil, Bert; Wee, Wen; J. Cohen, Steven; L. Aisner, Dara; R. Menter, Alex; Abdulaziz Tejani, Mohamedtaki; K. Cho, Jonathan; Rubin, Peter; L. Coveler, Andrew; Olanrele Olowokure, Olugbenga; Baranda, Joaquina; Cusnir, Mike; Agop Philip, Philip; Boles, Jeremiah; T. Maguire, Robert; Wilhelm, François; Maniar, Manoj; L. Gomes, Christina; A. Messersmith, Wells

doi:10.1200/jco.2015.33.15_suppl.4117

Public

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Published in Journal of Clinical Oncology • May 20, 2015

Authors:

Aaron J. Scott

Bert H. O’Neil

Wen Wee

Abstract

4117 Background: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was asse...

Subject

Gemcitabine

Medicine

Pancreatic cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!